What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Endocrinology
His main research concerns Internal medicine, Endocrinology, Metabolic syndrome, Diabetes mellitus and Cardiology.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His Endocrinology study integrates concerns from other disciplines, such as Statin, Platelet and Vascular disease.
His Statin research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Intensive care medicine, Meta-analysis and Combination therapy, Pharmacology.
His research integrates issues of Weight loss and Fatty liver in his study of Metabolic syndrome.
His work in Cardiology covers topics such as Stroke which are related to areas like Surgery and Odds ratio.
His most cited work include:
- Mean Platelet Volume: A Link Between Thrombosis and Inflammation? (731 citations)
- Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis (466 citations)
- The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis (462 citations)
What are the main themes of his work throughout his whole career to date?
Dimitri P. Mikhailidis mainly focuses on Internal medicine, Endocrinology, Cardiology, Diabetes mellitus and Pharmacology.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
His study in Type 2 Diabetes Mellitus, Prostacyclin, Insulin resistance, Dyslipidemia and Insulin is carried out as part of his studies in Endocrinology.
In his study, which falls under the umbrella issue of Cardiology, Risk factor is strongly linked to Vascular disease.
His work deals with themes such as Statin and Ezetimibe, which intersect with Pharmacology.
As part of his studies on Disease, Dimitri P. Mikhailidis often connects relevant subjects like Intensive care medicine.
He most often published in these fields:
- Internal medicine (68.40%)
- Endocrinology (33.94%)
- Cardiology (20.70%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (68.40%)
- Disease (11.12%)
- Diabetes mellitus (16.39%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Disease, Diabetes mellitus, Cardiology and Endocrinology.
Dimitri P. Mikhailidis interconnects Gastroenterology and Type 2 Diabetes Mellitus in the investigation of issues within Internal medicine.
His Disease research includes themes of Bioinformatics and Intensive care medicine.
While the research belongs to areas of Intensive care medicine, Dimitri P. Mikhailidis spends his time largely on the problem of Statin, intersecting his research to questions surrounding Combination therapy and Dyslipidemia.
Many of his studies involve connections with topics such as Stroke and Cardiology.
His biological study deals with issues like Pharmacology, which deal with fields such as Cholesterol.
Between 2015 and 2021, his most popular works were:
- Non-alcoholic fatty liver disease and dyslipidemia: An update (165 citations)
- Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. (143 citations)
- The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. (137 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Diabetes mellitus
His scientific interests lie mostly in Internal medicine, Meta-analysis, Endocrinology, Confidence interval and Randomized controlled trial.
His studies deal with areas such as Gastroenterology, Type 2 Diabetes Mellitus and Cardiology as well as Internal medicine.
His study in Meta-analysis is interdisciplinary in nature, drawing from both Prospective cohort study, Surgery, Statistical significance and Lipoprotein.
In his work, Dimitri P. Mikhailidis performs multidisciplinary research in Endocrinology and Context.
His research in Confidence interval intersects with topics in Proportional hazards model, Plasma lipids, Atorvastatin and Rosuvastatin.
His Randomized controlled trial study combines topics in areas such as Clinical trial, Adverse effect, Pharmacology, Placebo and Metabolism.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
